Filing Flows › Companies › Hims & Hers Health › Timeline
Hims & Hers Health stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−37.3% to $26.00
Hims & Hers Health (HIMS) stock fell 37% over the last 252 sessions, to $26.00. On the way it reported 3 quarters, its insiders filed 1 open-market trade and 14 Form 144 notices of planned sales, and the company filed 6 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 28, 2026 | Form 144 | Form 144: Soleil Boughton plans to sell $96K | +4.9% (+4.5% vs SPY) | −8.3% (−6.3% vs SPY) | — |
| Oct 14, 2026 | Form 144 | Form 144: Soleil Boughton plans to sell $101K | −6.9% (−5.8% vs SPY) | −1.7% (−0.5% vs SPY) | — |
| Oct 7, 2026 | 8-K | Directors and officers: departures, appointments, pay | −5.1% (−4.7% vs SPY) | −6.3% (−5.4% vs SPY) | −20.5% (−14.6% vs SPY) |
| Oct 1, 2026 | Form 144 | Form 144: Oluyemi Okupe plans to sell $59K | −1.7% (−1.8% vs SPY) | −0.8% (−2.7% vs SPY) | −0.4% (−1.3% vs SPY) |
| Sep 30, 2026 | Form 144 | Form 144: Soleil Boughton plans to sell $101K | +3.7% (+3.9% vs SPY) | +2.6% (+0.7% vs SPY) | +2.1% (+1.1% vs SPY) |
| Sep 22, 2026 | Form 144 | Form 144: Oluyemi Okupe plans to sell $877K | +3.6% (+3.6% vs SPY) | −2.0% (−0.9% vs SPY) | −0.5% (+0.1% vs SPY) |
| Sep 17, 2026 | Form 144 | Form 144: Oluyemi Okupe plans to sell $355K | −0.4% (−1.5% vs SPY) | +1.4% (−0.7% vs SPY) | +4.8% (+2.2% vs SPY) |
| Sep 16, 2026 | Form 144 | Form 144: Soleil Boughton plans to sell $174K | +0.5% (+1.0% vs SPY) | +8.9% (+6.5% vs SPY) | −0.5% (−2.3% vs SPY) |
| Sep 15, 2026 | Form 144 | Form 144: Michael Chi plans to sell $398K | −3.4% (−2.9% vs SPY) | +1.9% (0.0% vs SPY) | +3.1% (+0.6% vs SPY) |
| Sep 15, 2026 | Form 144 | Form 144: Mohamed Elshenawy plans to sell $226K | −3.4% (−2.9% vs SPY) | +1.9% (0.0% vs SPY) | +3.1% (+0.6% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Soleil Boughton plans to sell $98K | +0.8% (+0.4% vs SPY) | −1.9% (−2.0% vs SPY) | +3.0% (+2.5% vs SPY) |
| Aug 19, 2026 | Form 144 | Form 144: Soleil Boughton plans to sell $692K | +12.7% (+12.5% vs SPY) | +14.8% (+15.0% vs SPY) | +1.8% (+2.4% vs SPY) |
| Aug 18, 2026 | Form 144 | Form 144: Deborah M. Autor plans to sell $467K | −4.4% (−3.7% vs SPY) | +8.3% (+9.5% vs SPY) | −2.2% (+0.3% vs SPY) |
| Aug 10, 2026 | Earnings | Earnings: missed the EPS estimate by -640.0% | +0.6% (+0.6% vs SPY) | −11.5% (−11.9% vs SPY) | −11.5% (−10.5% vs SPY) |
| Jul 22, 2026 | Form 144 | Form 144: Christiane Pendarvis plans to sell $113K | −3.3% (−3.1% vs SPY) | −11.0% (−10.0% vs SPY) | −5.2% (−7.9% vs SPY) |
| Jul 17, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.4% (−0.3% vs SPY) | −15.6% (−15.0% vs SPY) | −13.8% (−17.7% vs SPY) |
| Jul 6, 2026 | Form 144 | Form 144: Oluyemi Okupe plans to sell $1.1M | +3.9% (+3.1% vs SPY) | −6.8% (−8.2% vs SPY) | −17.7% (−19.5% vs SPY) |
| Jul 1, 2026 | 8-K | Material definitive agreement | −2.1% (−1.9% vs SPY) | −5.8% (−6.6% vs SPY) | −30.2% (−30.4% vs SPY) |
| Jun 2, 2026 | 8-K | Material definitive agreement | −0.9% (−1.0% vs SPY) | −2.1% (+0.4% vs SPY) | +30.3% (+31.7% vs SPY) |
| May 26, 2026 | Insider buy | Wells David B bought $1.2M | +0.4% (−0.2% vs SPY) | +15.6% (+13.9% vs SPY) | +32.0% (+33.4% vs SPY) |
| May 21, 2026 | 8-K | Material definitive agreement | −1.1% (−1.5% vs SPY) | +8.5% (+6.7% vs SPY) | +31.7% (+32.7% vs SPY) |
| May 11, 2026 | Earnings | Earnings: missed the EPS estimate by -1664.3% | +3.0% (+2.8% vs SPY) | −12.1% (−12.3% vs SPY) | +2.5% (+2.5% vs SPY) |
| Feb 23, 2026 | Earnings | Earnings: beat the EPS estimate by 92.5% | −0.8% (+0.3% vs SPY) | −7.4% (−6.9% vs SPY) | +36.2% (+41.1% vs SPY) |
| Feb 19, 2026 | 8-K | Material definitive agreement | −0.1% (+0.1% vs SPY) | −0.1% (−1.1% vs SPY) | +42.2% (+46.2% vs SPY) |
Insiders’ record here
In the year on the chart, Hims & Hers Health's insiders reported 1 open-market buy ($1.2M) and 0 sales ($0). Of the 1 old enough to score, 1 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was +31.1% and after a sale —.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Hims & Hers Health: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.